Remodulin and Bursitis - a phase IV clinical study of FDA data


We study 52,540 people who have side effects when taking Remodulin. Bursitis is found, especially among people who are female, 60+ old, also take Opsumit and have Pulmonary hypertension.

The phase IV clinical study analyzes which people take Remodulin and have Bursitis. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 28, 2023

52,540 people reported to have side effects when taking Remodulin.
Among them, 9 people (0.02%) have Bursitis.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is used in primary pulmonary hypertension. Currently, eHealthMe is studying from 52,567 Remodulin users.

What is Bursitis?

Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder) is found to be associated with 1,670 drugs and 1,039 conditions by eHealthMe. Currently, we are studying 17,138 people who have Bursitis.

Number of Remodulin and Bursitis reports submitted per year:

Could Remodulin cause Bursitis?

Gender of people who have Bursitis when taking Remodulin *:

  • female: 88.89 %
  • male: 11.11 %

Age of people who have Bursitis when taking Remodulin *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 16.67 %
  • 50-59: 0.0 %
  • 60+: 83.33 %

Common drugs people take besides Remodulin *:

  1. Opsumit: 4 people, 44.44%
  2. Eliquis: 2 people, 22.22%
  3. Warfarin Sodium: 1 person, 11.11%
  4. Hydrocortisone: 1 person, 11.11%
  5. Adempas: 1 person, 11.11%
  6. Ambrisentan: 1 person, 11.11%
  7. Amlodipine: 1 person, 11.11%
  8. Coumadin: 1 person, 11.11%
  9. Elidel: 1 person, 11.11%
  10. Letairis: 1 person, 11.11%

Common side effects people have besides Bursitis *:

  1. Weakness: 3 people, 33.33%
  2. Breathing Difficulty: 3 people, 33.33%
  3. Fall: 3 people, 33.33%
  4. Pain In Extremity: 3 people, 33.33%
  5. Hypotension (abnormally low blood pressure): 3 people, 33.33%
  6. Limb Injury: 2 people, 22.22%
  7. Back Pain: 2 people, 22.22%
  8. Exercise Tolerance Decreased: 2 people, 22.22%
  9. Hand Fracture: 2 people, 22.22%
  10. Head Injury: 2 people, 22.22%

Common conditions people have *:

  1. Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 22.22%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and have Bursitis?

Check whether Bursitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Remodulin side effects by duration, gender and age:

Bursitis treatments and more:

Common drugs associated with Bursitis:

All the drugs that are associated with Bursitis:

Common conditions associated with Bursitis:

All the conditions that are associated with Bursitis:

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Remodulin) and Remodulin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: